Literature DB >> 22805771

Stable size distribution of amyloid plaques over the course of Alzheimer disease.

Alberto Serrano-Pozo1, Matthew L Mielke, Alona Muzitansky, Teresa Gómez-Isla, John H Growdon, Brian J Bacskai, Rebecca A Betensky, Matthew P Frosch, Bradley T Hyman.   

Abstract

Amyloid β plaques are a key pathologic feature of Alzheimer disease (AD), but whether plaque sizes increase or stabilize over the course of AD is unknown. We measured the size distribution of total immunoreactive (10D5-positive) and dense-core (Thioflavin S-positive) plaques in the temporal neocortex of a large group of subjects with AD and age-matched plaque-bearing subjects without dementia to test the hypothesis that amyloid plaques continue to grow along with the progression of the disease. The size of amyloid β (10D5)-positive plaques did not differ between groups, whereas dense-core plaques from the group with AD were slightly larger than those from the group without dementia (∼25%-30%, p = 0.01). Within the group with AD, dense-core plaque size did not independently correlate with duration of clinical disease (from 4 to 21 years, p = 0.68), whereas 10D5-positive plaque size correlated negatively with disease duration (p = 0.01). By contrast, an earlier age of symptom onset strongly predicted a larger postmortem plaque size; this effect was independent of disease duration and the presence of the APOE[Latin Small Letter Open E]4 allele (p = 0.0001). We conclude that plaques vary in size among patients, with larger size distributions correlating with an earlier age of onset, but plaques do not substantially increase in size over the clinical course of the disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22805771      PMCID: PMC3407299          DOI: 10.1097/NEN.0b013e31825e77de

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  61 in total

1.  Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates.

Authors:  D M Walsh; D M Hartley; Y Kusumoto; Y Fezoui; M M Condron; A Lomakin; G B Benedek; D J Selkoe; D B Teplow
Journal:  J Biol Chem       Date:  1999-09-03       Impact factor: 5.157

2.  Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease.

Authors:  Victor L Villemagne; Kerryn E Pike; Gaël Chételat; Kathryn A Ellis; Rachel S Mulligan; Pierrick Bourgeat; Uwe Ackermann; Gareth Jones; Cassandra Szoeke; Olivier Salvado; Ralph Martins; Graeme O'Keefe; Chester A Mathis; William E Klunk; David Ames; Colin L Masters; Christopher C Rowe
Journal:  Ann Neurol       Date:  2011-01       Impact factor: 10.422

3.  Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques.

Authors:  Robert M Koffie; Melanie Meyer-Luehmann; Tadafumi Hashimoto; Kenneth W Adams; Matthew L Mielke; Monica Garcia-Alloza; Kristina D Micheva; Stephen J Smith; M Leo Kim; Virginia M Lee; Bradley T Hyman; Tara L Spires-Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-19       Impact factor: 11.205

4.  Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate.

Authors:  D M Walsh; A Lomakin; G B Benedek; M M Condron; D B Teplow
Journal:  J Biol Chem       Date:  1997-08-29       Impact factor: 5.157

Review 5.  Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease.

Authors: 
Journal:  Neurobiol Aging       Date:  1997 Jul-Aug       Impact factor: 4.673

6.  Reversible in vitro growth of Alzheimer disease beta-amyloid plaques by deposition of labeled amyloid peptide.

Authors:  J E Maggio; E R Stimson; J R Ghilardi; C J Allen; C E Dahl; D C Whitcomb; S R Vigna; H V Vinters; M E Labenski; P W Mantyh
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

7.  Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease.

Authors:  T Gomez-Isla; H L West; G W Rebeck; S D Harr; J H Growdon; J J Locascio; T T Perls; L A Lipsitz; B T Hyman
Journal:  Ann Neurol       Date:  1996-01       Impact factor: 10.422

8.  Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease.

Authors:  P V Arriagada; K Marzloff; B T Hyman
Journal:  Neurology       Date:  1992-09       Impact factor: 9.910

9.  The progression of the pathological changes of Alzheimer's disease in frontal and temporal neocortex examined both at biopsy and at autopsy.

Authors:  D M Mann; B Marcyniuk; P O Yates; D Neary; J S Snowden
Journal:  Neuropathol Appl Neurobiol       Date:  1988 May-Jun       Impact factor: 8.090

10.  Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls.

Authors:  N M Scheinin; S Aalto; J Koikkalainen; J Lötjönen; M Karrasch; N Kemppainen; M Viitanen; K Någren; S Helin; M Scheinin; J O Rinne
Journal:  Neurology       Date:  2009-09-02       Impact factor: 9.910

View more
  16 in total

Review 1.  The Essential Role of Soluble Aβ Oligomers in Alzheimer's Disease.

Authors:  Zi-Xuan Wang; Lan Tan; Jinyuan Liu; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2015-04-02       Impact factor: 5.590

2.  Differential relationships of reactive astrocytes and microglia to fibrillar amyloid deposits in Alzheimer disease.

Authors:  Alberto Serrano-Pozo; Alona Muzikansky; Teresa Gómez-Isla; John H Growdon; Rebecca A Betensky; Matthew P Frosch; Bradley T Hyman
Journal:  J Neuropathol Exp Neurol       Date:  2013-06       Impact factor: 3.685

3.  Four-dimensional microglia response to anti-Aβ treatment in APP/PS1xCX3CR1/GFP mice.

Authors:  Monica Garcia-Alloza; Laura A Borrelli; Diana H Thyssen; Suzanne E Hickman; Joseph El Khoury; Brian J Bacskai
Journal:  Intravital       Date:  2013-04-01

4.  Microglia convert aggregated amyloid-β into neurotoxic forms through the shedding of microvesicles.

Authors:  P Joshi; E Turola; A Ruiz; A Bergami; D D Libera; L Benussi; P Giussani; G Magnani; G Comi; G Legname; R Ghidoni; R Furlan; M Matteoli; C Verderio
Journal:  Cell Death Differ       Date:  2013-12-13       Impact factor: 15.828

5.  Plaque-Associated Local Toxicity Increases over the Clinical Course of Alzheimer Disease.

Authors:  Alberto Serrano-Pozo; Rebecca A Betensky; Matthew P Frosch; Bradley T Hyman
Journal:  Am J Pathol       Date:  2015-12-11       Impact factor: 4.307

6.  Clinicopathological Staging of Dynamics of Neurodegeneration and Neuronal Loss in Alzheimer Disease.

Authors:  Jerzy Wegiel; Michael Flory; Izabela Kuchna; Krzysztof Nowicki; Shuang Yong Ma; Jarek Wegiel; Eulalia Badmaev; Mony de Leon; Thomas Wisniewski; Barry Reisberg
Journal:  J Neuropathol Exp Neurol       Date:  2021-01-01       Impact factor: 3.685

7.  Effect of APOE alleles on the glial transcriptome in normal aging and Alzheimer's disease.

Authors:  Alberto Serrano-Pozo; Zhaozhi Li; Ayush Noori; Huong N Nguyen; Aziz Mezlini; Liang Li; Eloise Hudry; Rosemary J Jackson; Bradley T Hyman; Sudeshna Das
Journal:  Nat Aging       Date:  2021-10-11

8.  Distinct cytokine profiles in human brains resilient to Alzheimer's pathology.

Authors:  Isabel Barroeta-Espar; Laura D Weinstock; Beatriz G Perez-Nievas; Avery C Meltzer; Michael Siao Tick Chong; Ana C Amaral; Melissa E Murray; Krista L Moulder; John C Morris; Nigel J Cairns; Joseph E Parisi; Val J Lowe; Ronald C Petersen; Julia Kofler; Milos D Ikonomovic; Oscar López; William E Klunk; Richard P Mayeux; Matthew P Frosch; Levi B Wood; Teresa Gomez-Isla
Journal:  Neurobiol Dis       Date:  2018-10-15       Impact factor: 5.996

9.  Microfluidic chemotaxis platform for differentiating the roles of soluble and bound amyloid-β on microglial accumulation.

Authors:  Hansang Cho; Tadafumi Hashimoto; Elisabeth Wong; Yukiko Hori; Levi B Wood; Lingzhi Zhao; Kevin M Haigis; Bradley T Hyman; Daniel Irimia
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

10.  Clustering of plaques contributes to plaque growth in a mouse model of Alzheimer's disease.

Authors:  Joanna F McCarter; Sabine Liebscher; Teresa Bachhuber; Claudia Abou-Ajram; Mark Hübener; Bradley T Hyman; Christian Haass; Melanie Meyer-Luehmann
Journal:  Acta Neuropathol       Date:  2013-06-18       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.